US2005123610A1PendingUtilityA1

Composition of a polypeptide and an amphiphilic compound in an ionic complex and the use thereof

51
Priority: Sep 1, 1998Filed: Jan 10, 2005Published: Jun 9, 2005
Est. expirySep 1, 2018(expired)· nominal 20-yr term from priority
Inventors:Apollon Papadimitriou
A61P 43/00A61P 25/00A61P 19/00A61K 47/6903A61K 9/0019A61K 47/28A61K 47/542A61K 47/554A61K 47/541A61K 9/19A61K 47/24A61K 47/54A61K 47/69A61K 9/0024A61K 47/544A61K 47/12A61K 38/1703A61K 9/0014A61K 47/543A61K 38/18
51
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A water-soluble composition containing a complex of an ionic pharmaceutically effective interleukin, characterized in that said composition contains, in addition, an amphiphilic compound, said interleukin and said amphiphilic compound forming an ionic complex, whereby the forming of the complex does not enhance the solubility of said interleukin, is suitable for increasing the activity of the interleukin and/or for the delayed release of the interleukin.

Claims

exact text as granted — not AI-modified
1 . A controlled-release pharmaceutical composition comprising an ionic complex precipitate comprising a polypeptide and an amphiphilic compound, wherein the ionic complex is precipitated in an environment which differs by at least 0.5 pH units from both the polypeptide's pK value and the amphiphilic compound's pK value.  
     
     
         2 . The controlled-release pharmaceutical composition of  claim 1  wherein the complex is embedded in a carrier.  
     
     
         3 . The controlled-release pharmaceutical composition of  claim 1  wherein the complex is embedded in a biocompatible carrier.  
     
     
         4 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is a hedgehog protein.  
     
     
         5 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is a bone morphogenetic protein.  
     
     
         6 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is a growth factor.  
     
     
         7 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is erythropoietin.  
     
     
         8 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is thrombopoietin.  
     
     
         9 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is G-CSF.  
     
     
         10 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is an interleukin.  
     
     
         11 . The controlled-release pharmaceutical composition of  claim 1  wherein the polypeptide is an interferon.  
     
     
         12 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is deoxycholate.  
     
     
         13 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is cholate.  
     
     
         14 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is taurcholate.  
     
     
         15 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is taurodeoxcholate.  
     
     
         16 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is dehydrocholate.  
     
     
         17 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is 3[(3-cholamidopropyl)dimethylammonio]-1 propane sulfonate.  
     
     
         18 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is N-dodecyl-N,N-dimethyl-3-ammonio-1-propane sulfonate.  
     
     
         19 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is palmitic acid.  
     
     
         20 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is alkyl sulfonate.  
     
     
         21 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is decyl sulfonate.  
     
     
         22 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is phosphatidyl serine.  
     
     
         23 . The controlled-release pharmaceutical composition of  claim 1  wherein the amphiphilic compound is phosphatidate.  
     
     
         24 . A method of treating a disease or condition comprising locally applying the composition of  claim 1  to the body of a patient in need of treatment.  
     
     
         25 . The method of  claim 24  wherein the disease or condition is a defect in bone.  
     
     
         26 . The method of  claim 24  wherein the disease or condition is a defect in cartilage.  
     
     
         27 . The controlled-release pharmaceutical composition of  claim 1  wherein the activity of the polypeptide is more active in said ionic complex than when said polypeptide is not in said ionic complex.

Join the waitlist — get patent alerts

Track US2005123610A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.